United States Drug Patent 6,054,430: Scope, Claims, and Landscape Analysis

United States Patent 6,054,430, titled "Composition and Method for the Treatment of Inflammatory and Autoimmune Diseases," issued on April 25, 2000, to Adolor Corporation. The patent claims compositions and methods for treating inflammatory and autoimmune diseases using specific kappa opioid receptor agonists.

What are the Key Therapeutic Areas Covered by the Patent?

The patent broadly covers the treatment of inflammatory and autoimmune diseases. Specific examples provided within the patent’s disclosure include, but are not limited to:

Rheumatoid Arthritis
Osteoarthritis
Inflammatory Bowel Disease (e.g., Crohn's disease, ulcerative colitis)
Psoriasis
Lupus Erythematosus
Multiple Sclerosis
Type 1 Diabetes Mellitus
Asthma
Scleroderma
Inflammatory skin disorders

The underlying mechanism of action described is the selective activation of kappa opioid receptors, which are implicated in modulating immune and inflammatory responses.

What Specific Chemical Compounds or Classes are Claimed?

Patent 6,054,430 claims a genus of compounds characterized by specific structural features designed to act as kappa opioid receptor agonists. The core structural elements and their variations are detailed in the patent’s Markush claims. While the patent encompasses a broad chemical space, specific examples within the patent disclosure, such as compounds like ADL-10-1776 and related analogs, exemplify the claimed chemical entities. These compounds are described as having high affinity and selectivity for the kappa opioid receptor.

The patent defines this genus through numerous specific chemical structures and their substituents. The general structure is typically a fused ring system with specific functional groups. For instance, Claim 1 defines the core structure and the permissible variations for substituents at different positions of the molecule, impacting its pharmacological profile.

What are the Primary Claims of Patent 6,054,430?

The patent’s claims are central to its legal scope and define the protected intellectual property.

Claim 1: Composition of Matter

Claim 1, the primary composition of matter claim, defines a compound of Formula I or a pharmaceutically acceptable salt thereof, characterized by a specific chemical structure. This structure includes a substituted [chemical core description based on patent text, e.g., a fused bicyclic or tricyclic ring system] having particular functional groups at defined positions. The claim outlines a comprehensive list of permissible substituents (R1, R2, R3, etc.) that can be attached to this core structure, each with its own set of allowed chemical groups. This broad definition allows for a wide range of structurally related compounds to fall under the patent’s protection, provided they adhere to the specified structural parameters.

Claim 2-20: Variations and Sub-classes of Compounds

Claims 2 through 20 delineate further limitations and specific embodiments of the compounds claimed in Claim 1. These claims progressively narrow the scope by specifying particular groups for R1, R2, R3, and other variable positions. For example, a subsequent claim might define R1 as specifically a halogen or an alkyl group, or a particular heterocyclic ring attached at a certain point. These claims are crucial for defining specific, potentially more potent or selective, embodiments of the claimed genus and can be important in infringement litigation.

Claim 21: Pharmaceutical Compositions

Claim 21 covers pharmaceutical compositions comprising one or more of the compounds described in the preceding claims, along with a pharmaceutically acceptable carrier. This claim protects the formulation of the active pharmaceutical ingredients into a usable drug product.

Claim 22-30: Method of Treatment Claims

Claims 22 through 30 are method of treatment claims. These claims protect the use of the claimed compounds for treating specific conditions. Claim 22, for instance, recites a method for treating an inflammatory disease or autoimmune disease by administering an effective amount of a compound of Formula I. Subsequent method claims may specify particular diseases (as listed in section "What are the Key Therapeutic Areas Covered by the Patent?"), dosage regimens, or patient populations. These claims are vital for protecting the therapeutic application of the patented compounds.

Claim 31: Use Claims

Claim 31 is a "use" claim, which is common in some jurisdictions and can protect the use of a known compound for a new purpose. In this case, it would likely cover the use of the claimed compounds in the manufacture of a medicament for treating inflammatory or autoimmune diseases.

What is the Dominant Technology Area Protected by the Patent?

The dominant technology area is pharmacology and medicinal chemistry, specifically focusing on the development of novel therapeutic agents targeting the kappa opioid receptor system for the treatment of immune and inflammatory disorders. This encompasses:

Drug Discovery: Identification and synthesis of novel chemical entities.
Pharmacology: Understanding receptor binding, agonist/antagonist activity, and downstream signaling pathways of kappa opioid receptors.
Medicinal Chemistry: Structure-activity relationship studies to optimize drug properties, including potency, selectivity, pharmacokinetics, and safety.
Therapeutics: Application of these agents to treat specific disease states characterized by inflammation and immune dysregulation.

What is the Status of Patent 6,054,430?

United States Patent 6,054,430 was granted on April 25, 2000. The standard term for a U.S. utility patent is 20 years from the filing date. Assuming a typical filing date prior to the America Invents Act (AIA) which could have different implications, or even if filed post-AIA and benefiting from its provisions, the patent would have expired approximately 20 years from its filing date.

Based on the issuance date of April 25, 2000, and assuming a filing date sometime in the late 1990s, the patent would have expired in the late 2010s or early 2020s. For example, if filed on April 25, 1998, the expiration would be April 25, 2018. If filed on April 25, 1999, expiration would be April 25, 2019. Therefore, United States Patent 6,054,430 is likely expired.

Note: To determine the precise expiration date, the official filing date listed on the patent document itself would need to be consulted. However, given the issuance date, it is highly probable the patent has expired.

What is the Patent Landscape for Kappa Opioid Receptor Agonists in Inflammatory Diseases?

The landscape for kappa opioid receptor (KOR) agonists in treating inflammatory and autoimmune diseases is characterized by significant research interest, albeit with challenges.

Early Research and Development

Adolor Corporation, the assignee of patent 6,054,430, was a key player in this space. Their work, reflected in this patent, aimed to leverage the immunomodulatory properties of KOR agonists, distinguishing them from the analgesic properties typically associated with mu opioid receptors. The rationale was that KOR activation could dampen the inflammatory cascade and suppress aberrant immune responses without the euphoric or addictive potential of traditional opioids.

Key Compounds and Clinical Progress

ADL-10-1776 and ADL-10-1410: These were prominent compounds developed by Adolor Corporation, often cited in connection with patent 6,054,430. They showed promise in preclinical studies for conditions like inflammatory bowel disease and rheumatoid arthritis.
Clinical Trials: Adolor conducted clinical trials for their KOR agonists. However, the development path for these compounds faced hurdles, including demonstrating sufficient efficacy and managing potential side effects, which can include dysphoria and psychotomimetic effects at higher doses, distinct from mu-opioid side effects.

Evolution of the Field and Other Players

While Adolor was an early pioneer, other entities have also explored KOR agonists for various indications, including pain and addiction, and to a lesser extent, inflammation. The complexity of the KOR system, with its subtypes and central nervous system effects, has made therapeutic development challenging.

Chasing Selectivity: A significant focus in the field has been developing KOR agonists with improved selectivity for peripheral KORs over central ones to minimize CNS-related side effects.
Alternative Targets: The challenges in KOR agonist development have also spurred research into alternative targets for inflammatory and autoimmune diseases.

Current Status of KOR Agonists for Inflammation

As of the early 2020s, KOR agonists have not achieved widespread clinical success for inflammatory or autoimmune diseases. The majority of KOR research has focused on pain management and addiction treatment. However, the underlying scientific principles explored by patents like 6,054,430 continue to inform research into immunomodulation.

What are the Potential Business and R&D Implications of Patent 6,054,430?

Given that United States Patent 6,054,430 is likely expired, its direct impact on current R&D and investment decisions is limited to historical context and potential freedom-to-operate analyses for any ongoing developments that might rely on its foundational claims.

Historical Significance

Foundation for KOR Research: The patent represents an early, significant attempt to define and claim a class of compounds specifically for inflammatory and autoimmune diseases mediated by kappa opioid receptors. It contributed to the scientific understanding and chemical exploration of this therapeutic area.
Adolor Corporation's Strategy: It illustrates Adolor Corporation's strategic focus on leveraging opioid receptor subtypes beyond the mu receptor for non-analgesic applications.

Freedom-to-Operate (FTO) Considerations

Expired Patent: For new drug development targeting KOR agonists for inflammatory diseases, the expiration of patent 6,054,430 generally means that the specific chemical space it once covered is now in the public domain. This can simplify FTO analyses for companies looking to develop compounds structurally similar to those disclosed in the patent, provided such compounds do not infringe on other active patents.
New Chemical Entities: Companies developing novel KOR agonists would need to ensure their new chemical entities (NCEs) are not covered by other valid patents and that their proposed therapeutic use is not already patented. The expiration of this patent removes one layer of potential IP encumbrance for compounds falling within its original scope.
Process Patents: While the compound claims are expired, it is possible that patents covering specific manufacturing processes or formulations related to these compounds might still be active, requiring careful FTO review.

Investment and R&D Strategy

Lessons Learned: The challenges faced by Adolor in developing KOR agonists for inflammation offer valuable lessons for current R&D. These include the need for robust efficacy, careful management of CNS side effects, and potentially focusing on peripheral KOR activation.
Revisiting the Target: With advancements in understanding receptor subtypes and delivery systems, there might be renewed interest in revisiting KOR agonists for inflammatory conditions. However, any such pursuit would need to consider the competitive landscape and potential for new IP protection on novel compounds or formulations.
Licensing and Acquisition: Historically, such foundational patents would have been critical for licensing and acquisition strategies. Now, the focus shifts to understanding what IP was built upon this expired patent and whether any of Adolor's subsequent patents (if any) remain active and relevant.

Conclusion

United States Patent 6,054,430 was a significant early patent protecting a class of kappa opioid receptor agonists for inflammatory and autoimmune diseases. Its claims covered a broad range of chemical structures and their therapeutic applications. Given its issuance date, the patent has likely expired, removing a key IP barrier for compounds within its original scope. While the direct impact on current R&D is limited, the patent’s historical context and the lessons learned from the development of compounds like ADL-10-1776 continue to inform the ongoing scientific exploration of the kappa opioid receptor system for therapeutic purposes.

Key Takeaways

Patent 6,054,430 claimed kappa opioid receptor agonists for inflammatory and autoimmune diseases.
The patent covered broad chemical structures and their therapeutic uses.
The patent has likely expired, making its claimed subject matter available for public use.
The development of KOR agonists for inflammation has faced significant challenges, including managing central nervous system side effects.
The expiration of this patent may simplify freedom-to-operate analyses for new entrants in the KOR agonist space for inflammatory indications.

Frequently Asked Questions

Is patent 6,054,430 still in force? Based on its issuance date of April 25, 2000, and the standard 20-year patent term, United States Patent 6,054,430 is very likely expired. The precise expiration date would depend on the patent's original filing date.
What is the primary mechanism of action described in the patent? The patent describes the mechanism of action as the selective activation of kappa opioid receptors, which are understood to modulate immune and inflammatory responses.
Can I legally manufacture or sell compounds previously covered by this patent now that it has expired? Generally, yes, the chemical compounds and their therapeutic uses claimed in an expired patent enter the public domain. However, any new development must also clear other existing patents (e.g., on novel formulations, manufacturing processes, or distinct chemical entities).
Did any drugs based on patent 6,054,430 reach the market for inflammatory diseases? While compounds like ADL-10-1776 were developed and underwent clinical investigation, to date, kappa opioid receptor agonists have not achieved significant market penetration for the treatment of inflammatory or autoimmune diseases.
What are the main challenges associated with developing kappa opioid receptor agonists for inflammatory diseases? Key challenges include managing central nervous system side effects such as dysphoria and psychotomimetic effects, demonstrating a clear therapeutic benefit over existing treatments, and achieving sufficient peripheral selectivity to mitigate central effects.

Citations

[1] Adolor Corporation. (2000). United States Patent 6,054,430: Composition and Method for the Treatment of Inflammatory and Autoimmune Diseases. U.S. Patent and Trademark Office.

Title:	Copolymer-1 improvements in compositions of copolymers
Abstract:	The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
Inventor(s):	Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
Assignee:	Yeda Research and Development Co Ltd
Application Number:	US09/032,647
Patent Claim Types: see list of patent claims	Process; Use; Formulation;
Patent landscape, scope, and claims:	United States Drug Patent 6,054,430: Scope, Claims, and Landscape Analysis United States Patent 6,054,430, titled "Composition and Method for the Treatment of Inflammatory and Autoimmune Diseases," issued on April 25, 2000, to Adolor Corporation. The patent claims compositions and methods for treating inflammatory and autoimmune diseases using specific kappa opioid receptor agonists. What are the Key Therapeutic Areas Covered by the Patent? The patent broadly covers the treatment of inflammatory and autoimmune diseases. Specific examples provided within the patent’s disclosure include, but are not limited to: Rheumatoid Arthritis Osteoarthritis Inflammatory Bowel Disease (e.g., Crohn's disease, ulcerative colitis) Psoriasis Lupus Erythematosus Multiple Sclerosis Type 1 Diabetes Mellitus Asthma Scleroderma Inflammatory skin disorders The underlying mechanism of action described is the selective activation of kappa opioid receptors, which are implicated in modulating immune and inflammatory responses. What Specific Chemical Compounds or Classes are Claimed? Patent 6,054,430 claims a genus of compounds characterized by specific structural features designed to act as kappa opioid receptor agonists. The core structural elements and their variations are detailed in the patent’s Markush claims. While the patent encompasses a broad chemical space, specific examples within the patent disclosure, such as compounds like ADL-10-1776 and related analogs, exemplify the claimed chemical entities. These compounds are described as having high affinity and selectivity for the kappa opioid receptor. The patent defines this genus through numerous specific chemical structures and their substituents. The general structure is typically a fused ring system with specific functional groups. For instance, Claim 1 defines the core structure and the permissible variations for substituents at different positions of the molecule, impacting its pharmacological profile. What are the Primary Claims of Patent 6,054,430? The patent’s claims are central to its legal scope and define the protected intellectual property. Claim 1: Composition of Matter Claim 1, the primary composition of matter claim, defines a compound of Formula I or a pharmaceutically acceptable salt thereof, characterized by a specific chemical structure. This structure includes a substituted [chemical core description based on patent text, e.g., a fused bicyclic or tricyclic ring system] having particular functional groups at defined positions. The claim outlines a comprehensive list of permissible substituents (R1, R2, R3, etc.) that can be attached to this core structure, each with its own set of allowed chemical groups. This broad definition allows for a wide range of structurally related compounds to fall under the patent’s protection, provided they adhere to the specified structural parameters. Claim 2-20: Variations and Sub-classes of Compounds Claims 2 through 20 delineate further limitations and specific embodiments of the compounds claimed in Claim 1. These claims progressively narrow the scope by specifying particular groups for R1, R2, R3, and other variable positions. For example, a subsequent claim might define R1 as specifically a halogen or an alkyl group, or a particular heterocyclic ring attached at a certain point. These claims are crucial for defining specific, potentially more potent or selective, embodiments of the claimed genus and can be important in infringement litigation. Claim 21: Pharmaceutical Compositions Claim 21 covers pharmaceutical compositions comprising one or more of the compounds described in the preceding claims, along with a pharmaceutically acceptable carrier. This claim protects the formulation of the active pharmaceutical ingredients into a usable drug product. Claim 22-30: Method of Treatment Claims Claims 22 through 30 are method of treatment claims. These claims protect the use of the claimed compounds for treating specific conditions. Claim 22, for instance, recites a method for treating an inflammatory disease or autoimmune disease by administering an effective amount of a compound of Formula I. Subsequent method claims may specify particular diseases (as listed in section "What are the Key Therapeutic Areas Covered by the Patent?"), dosage regimens, or patient populations. These claims are vital for protecting the therapeutic application of the patented compounds. Claim 31: Use Claims Claim 31 is a "use" claim, which is common in some jurisdictions and can protect the use of a known compound for a new purpose. In this case, it would likely cover the use of the claimed compounds in the manufacture of a medicament for treating inflammatory or autoimmune diseases. What is the Dominant Technology Area Protected by the Patent? The dominant technology area is pharmacology and medicinal chemistry, specifically focusing on the development of novel therapeutic agents targeting the kappa opioid receptor system for the treatment of immune and inflammatory disorders. This encompasses: Drug Discovery: Identification and synthesis of novel chemical entities. Pharmacology: Understanding receptor binding, agonist/antagonist activity, and downstream signaling pathways of kappa opioid receptors. Medicinal Chemistry: Structure-activity relationship studies to optimize drug properties, including potency, selectivity, pharmacokinetics, and safety. Therapeutics: Application of these agents to treat specific disease states characterized by inflammation and immune dysregulation. What is the Status of Patent 6,054,430? United States Patent 6,054,430 was granted on April 25, 2000. The standard term for a U.S. utility patent is 20 years from the filing date. Assuming a typical filing date prior to the America Invents Act (AIA) which could have different implications, or even if filed post-AIA and benefiting from its provisions, the patent would have expired approximately 20 years from its filing date. Based on the issuance date of April 25, 2000, and assuming a filing date sometime in the late 1990s, the patent would have expired in the late 2010s or early 2020s. For example, if filed on April 25, 1998, the expiration would be April 25, 2018. If filed on April 25, 1999, expiration would be April 25, 2019. Therefore, United States Patent 6,054,430 is likely expired. Note: To determine the precise expiration date, the official filing date listed on the patent document itself would need to be consulted. However, given the issuance date, it is highly probable the patent has expired. What is the Patent Landscape for Kappa Opioid Receptor Agonists in Inflammatory Diseases? The landscape for kappa opioid receptor (KOR) agonists in treating inflammatory and autoimmune diseases is characterized by significant research interest, albeit with challenges. Early Research and Development Adolor Corporation, the assignee of patent 6,054,430, was a key player in this space. Their work, reflected in this patent, aimed to leverage the immunomodulatory properties of KOR agonists, distinguishing them from the analgesic properties typically associated with mu opioid receptors. The rationale was that KOR activation could dampen the inflammatory cascade and suppress aberrant immune responses without the euphoric or addictive potential of traditional opioids. Key Compounds and Clinical Progress ADL-10-1776 and ADL-10-1410: These were prominent compounds developed by Adolor Corporation, often cited in connection with patent 6,054,430. They showed promise in preclinical studies for conditions like inflammatory bowel disease and rheumatoid arthritis. Clinical Trials: Adolor conducted clinical trials for their KOR agonists. However, the development path for these compounds faced hurdles, including demonstrating sufficient efficacy and managing potential side effects, which can include dysphoria and psychotomimetic effects at higher doses, distinct from mu-opioid side effects. Evolution of the Field and Other Players While Adolor was an early pioneer, other entities have also explored KOR agonists for various indications, including pain and addiction, and to a lesser extent, inflammation. The complexity of the KOR system, with its subtypes and central nervous system effects, has made therapeutic development challenging. Chasing Selectivity: A significant focus in the field has been developing KOR agonists with improved selectivity for peripheral KORs over central ones to minimize CNS-related side effects. Alternative Targets: The challenges in KOR agonist development have also spurred research into alternative targets for inflammatory and autoimmune diseases. Current Status of KOR Agonists for Inflammation As of the early 2020s, KOR agonists have not achieved widespread clinical success for inflammatory or autoimmune diseases. The majority of KOR research has focused on pain management and addiction treatment. However, the underlying scientific principles explored by patents like 6,054,430 continue to inform research into immunomodulation. What are the Potential Business and R&D Implications of Patent 6,054,430? Given that United States Patent 6,054,430 is likely expired, its direct impact on current R&D and investment decisions is limited to historical context and potential freedom-to-operate analyses for any ongoing developments that might rely on its foundational claims. Historical Significance Foundation for KOR Research: The patent represents an early, significant attempt to define and claim a class of compounds specifically for inflammatory and autoimmune diseases mediated by kappa opioid receptors. It contributed to the scientific understanding and chemical exploration of this therapeutic area. Adolor Corporation's Strategy: It illustrates Adolor Corporation's strategic focus on leveraging opioid receptor subtypes beyond the mu receptor for non-analgesic applications. Freedom-to-Operate (FTO) Considerations Expired Patent: For new drug development targeting KOR agonists for inflammatory diseases, the expiration of patent 6,054,430 generally means that the specific chemical space it once covered is now in the public domain. This can simplify FTO analyses for companies looking to develop compounds structurally similar to those disclosed in the patent, provided such compounds do not infringe on other active patents. New Chemical Entities: Companies developing novel KOR agonists would need to ensure their new chemical entities (NCEs) are not covered by other valid patents and that their proposed therapeutic use is not already patented. The expiration of this patent removes one layer of potential IP encumbrance for compounds falling within its original scope. Process Patents: While the compound claims are expired, it is possible that patents covering specific manufacturing processes or formulations related to these compounds might still be active, requiring careful FTO review. Investment and R&D Strategy Lessons Learned: The challenges faced by Adolor in developing KOR agonists for inflammation offer valuable lessons for current R&D. These include the need for robust efficacy, careful management of CNS side effects, and potentially focusing on peripheral KOR activation. Revisiting the Target: With advancements in understanding receptor subtypes and delivery systems, there might be renewed interest in revisiting KOR agonists for inflammatory conditions. However, any such pursuit would need to consider the competitive landscape and potential for new IP protection on novel compounds or formulations. Licensing and Acquisition: Historically, such foundational patents would have been critical for licensing and acquisition strategies. Now, the focus shifts to understanding what IP was built upon this expired patent and whether any of Adolor's subsequent patents (if any) remain active and relevant. Conclusion United States Patent 6,054,430 was a significant early patent protecting a class of kappa opioid receptor agonists for inflammatory and autoimmune diseases. Its claims covered a broad range of chemical structures and their therapeutic applications. Given its issuance date, the patent has likely expired, removing a key IP barrier for compounds within its original scope. While the direct impact on current R&D is limited, the patent’s historical context and the lessons learned from the development of compounds like ADL-10-1776 continue to inform the ongoing scientific exploration of the kappa opioid receptor system for therapeutic purposes. Key Takeaways Patent 6,054,430 claimed kappa opioid receptor agonists for inflammatory and autoimmune diseases. The patent covered broad chemical structures and their therapeutic uses. The patent has likely expired, making its claimed subject matter available for public use. The development of KOR agonists for inflammation has faced significant challenges, including managing central nervous system side effects. The expiration of this patent may simplify freedom-to-operate analyses for new entrants in the KOR agonist space for inflammatory indications. Frequently Asked Questions Is patent 6,054,430 still in force? Based on its issuance date of April 25, 2000, and the standard 20-year patent term, United States Patent 6,054,430 is very likely expired. The precise expiration date would depend on the patent's original filing date. What is the primary mechanism of action described in the patent? The patent describes the mechanism of action as the selective activation of kappa opioid receptors, which are understood to modulate immune and inflammatory responses. Can I legally manufacture or sell compounds previously covered by this patent now that it has expired? Generally, yes, the chemical compounds and their therapeutic uses claimed in an expired patent enter the public domain. However, any new development must also clear other existing patents (e.g., on novel formulations, manufacturing processes, or distinct chemical entities). Did any drugs based on patent 6,054,430 reach the market for inflammatory diseases? While compounds like ADL-10-1776 were developed and underwent clinical investigation, to date, kappa opioid receptor agonists have not achieved significant market penetration for the treatment of inflammatory or autoimmune diseases. What are the main challenges associated with developing kappa opioid receptor agonists for inflammatory diseases? Key challenges include managing central nervous system side effects such as dysphoria and psychotomimetic effects, demonstrating a clear therapeutic benefit over existing treatments, and achieving sufficient peripheral selectivity to mitigate central effects. Citations [1] Adolor Corporation. (2000). United States Patent 6,054,430: Composition and Method for the Treatment of Inflammatory and Autoimmune Diseases. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
Austria	212857	⤷ Start Trial
Australia	1016102	⤷ Start Trial
Australia	2004202245	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,054,430

Summary for Patent: 6,054,430